Bioverativ Inc (BIVV):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C3048)
◆英語タイトル:Bioverativ Inc (BIVV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3048
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:45
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technology for the treatment of hemophilia A; and Alprolix, which comprises recombinant coagulation factor IX engineered using Fc fusion technology for the treatment of hemophilia B. The company’s pipeline encompasses investigational candidates for the treatment of cold agglutinin disease, hemophilia A, beta thalassemia sickle cell disease, hemophilia B, and Sickle cell disease. Bioverativ sells its products in the US, the European Union (EU), New Zealand, Canada, Australia, Japan, Switzerland, Iceland, Liechtenstein, and Norway. Bioverativ is headquartered in Waltham, Massachusetts, the US.

Bioverativ Inc (BIVV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bioverativ Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bioverativ Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bioverativ Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
True North Therapeutics Raises USD45 Million in Series D Financing 12
True North Therapeutics Raises USD40 Million in Series C Financing 13
True North Therapeutics Raises USD35 Million in Series B Financing 15
True North Therapeutics Raises USD22 Million in Series A Venture Financing 16
Partnerships 18
Bioverativ Enters into Research Agreement with Bicycle Therapeutics 18
Licensing Agreements 19
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 19
Acquisition 20
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 20
Bioverativ Therapeutics Acquires True North Therapeutics 22
Bioverativ Inc – Key Competitors 23
Bioverativ Inc – Key Employees 24
Bioverativ Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Feb 13, 2018: Bioverativ Reports Fourth Quarter and Full Year 2017 Performance 26
Oct 26, 2017: Bioverativ Reports Third Quarter 2017 Performance 28
Aug 02, 2017: Bioverativ Reports Second Quarter 2017 Performance 30
May 03, 2017: Bioverativ Reports First Quarter 2017 Results 32
Corporate Communications 34
May 15, 2017: Bioverativ Appoints Geno J. Germano to Company’s Board of Directors 34
Mar 02, 2017: Anna Protopapas to Join Bioverativ Board of Directors 35
Government and Public Interest 36
Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost $32 Million Boost from Stem Cell Agency 36
Product Approvals 38
Jun 12, 2017: Bioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat Hemophilia A 38
Clinical Trials 39
Jun 18, 2018: Cold Agglutinin Disease Associated with Greater Than Twofold Increased Risk of Mortality in First Five Years After Diagnosis 39
Mar 06, 2018: Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease 40
Dec 11, 2017: Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients 41
Nov 01, 2017: Bioverativ to Present New Data on BIVV009 at ASH 2017 Annual Meeting 43
Jan 10, 2017: True North Provides Corporate Update at J.P. Morgan Healthcare Conference 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Bioverativ Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bioverativ Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bioverativ Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Bioverativ Inc, Medical Devices Deals, 2012 to YTD 2018 10
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
True North Therapeutics Raises USD45 Million in Series D Financing 12
True North Therapeutics Raises USD40 Million in Series C Financing 13
True North Therapeutics Raises USD35 Million in Series B Financing 15
True North Therapeutics Raises USD22 Million in Series A Venture Financing 16
Bioverativ Enters into Research Agreement with Bicycle Therapeutics 18
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 19
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 20
Bioverativ Therapeutics Acquires True North Therapeutics 22
Bioverativ Inc, Key Competitors 23
Bioverativ Inc, Key Employees 24
Bioverativ Inc, Other Locations 25
Bioverativ Inc, Subsidiaries 25

List of Figures
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bioverativ Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bioverativ Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Bioverativ Inc (BIVV):製薬・医療:M&Aディール及び事業提携情報(Bioverativ Inc (BIVV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆